Plastic Surgery International

Plastic Surgery International / 2018 / Article

Corrigendum | Open Access

Volume 2018 |Article ID 5731290 | https://doi.org/10.1155/2018/5731290

Felix J. Paprottka, Nicco Krezdorn, Heiko Sorg, Sören Könneker, Stiliano Bontikous, Ian Robertson, Christopher L. Schlett, Nils-Kristian Dohse, Detlev Hebebrand, "Corrigendum to “Evaluation of Complication Rates after Breast Surgery Using Acellular Dermal Matrix: Median Follow-Up of Three Years”", Plastic Surgery International, vol. 2018, Article ID 5731290, 4 pages, 2018. https://doi.org/10.1155/2018/5731290

Corrigendum to “Evaluation of Complication Rates after Breast Surgery Using Acellular Dermal Matrix: Median Follow-Up of Three Years”

Received29 Apr 2018
Accepted17 May 2018
Published11 Jul 2018

In the article titled “Evaluation of Complication Rates after Breast Surgery Using Acellular Dermal Matrix: Median Follow-Up of Three Years” [1], there were errors, which should be corrected as follows.

(1) The title should be changed to “Evaluation of complication rates after breast surgery using two different kinds of Acellular Dermal Matrix and one Bovine Pericardium Collagen Membrane: median follow-up of three years.”

(2) Tables , , and along with their legends should be corrected as below.

(3) In the “Material and Methods,” the sentence reading “Sixteen patients had a history of radiotherapy prior to ADM implementation; see Table ” should be changed to “Sixteen patients had a history of radiotherapy prior to ADM implementation; see Table .

(4) In the “Discussion,” the sentence reading “Other limitations of our study include the relative brevity of follow-up with a mean time period of 36 months” should be changed to “Other limitations of our study include the relative brevity of follow-up with a median time period of 36 months.”

(5) The legends of Figures and 4 should be corrected where “capsular contracture and” should be added to the legend of Figure and “and capsular contracture, followed by” should be added to the legend of Figure . The corrected figures are as below.


ADMProductNumber of ADM implants usedNumber of treated patientsMedian patient age (years)Median follow-up time (months)

HADMEpiflex® / DIZG151246 (36-76)40 (20-50)
PADMStrattice® / LifeCell211656 (44-66)43 (30-54)
BADMTutomesh® / rti surgical161353 (33-74)20 (12-31)

totalall ADMs524152 (33-76)36 (12-54)

Listing of matrix, name of ADM-product and its fabricant, amount of breast reconstructions (BR)/augmentations with usage of ADMs, number of patients treated with ADMs, median patient age and range in years, and median follow-up time and range in months of the given patient collective, which received a breast reconstruction/augmentation with ADM; HADM: human ADM; PADM: porcine ADM; and BADM: bovine ADM.

Oncologic indicationAesthetic indication
ADMProductBR with ADM (n)BR with no capsular contracture BR with capsular contracture Primary augmentation Secondary augmentation after capsular contracture Secondary augmentation after aesthetic-related complications

HADMEpiflex® / DIZG1513920

PADMStrattice® / LifeCell2168520

BADMTutomesh® / rti surgical1625324

Listing of kind of matrix used, name of product, number of breast reconstructions with certain ADMs, and indications for ADM usage (breast reconstruction (BR) with no capsular contracture, BR with capsular contracture, primary augmentation, secondary augmentation after capsular contracture, or secondary augmentation after aesthetic-related complications including IMF-loss and insufficient implant coverage with breast tissue). Oncologic patients made up 27% of the HADM group, 67% of the PADM group, and 44% of the BADM group; HADM: human ADM, PADM: porcine ADM, and BADM: bovine ADM; denotes no history of radiotherapy; denote history of radiotherapy; denote primary augmentation in cases with large breasts; denote loss of IMF.

ADMHADM (Epiflex® / DIZG), PADM (Strattice® / LifeCell), BADM (Tutomesh® / rti surgical)
Breasts (total)52
Median follow-up time (in months)36 (12-54)
Complications (total)9 (17%)

Short-term complicationsSkin necrosis2 (4%)
Seroma1 (2%)
Haematoma0 (0%)
Infection2 (4%)
RBS3 (6%)

Long-term complicationsCapsular contracture3 (6%)
Implant malposition0 (0%)
Implant loss1 (2%)

Short-term (skin necrosis, seroma, haematoma, infection, and Red Breast Syndrome (RBS)) and long-term complications (capsular contracture, implant malposition, and implant loss) for all breasts with usage of ADMs (human ADM (HADM), porcine ADM (PADM), and bovine ADM (BADM)), median follow-up time for all patients, and total complications of all breasts being reconstructed with ADMs; denotes being excluded from overall complications and requiring further medical treatment; denote >Baker-St. II.

References

  1. F. J. Paprottka, N. Krezdorn, H. Sorg et al., “Evaluation of Complication Rates after Breast Surgery Using Acellular Dermal Matrix: Median Follow-Up of Three Years,” Plastic Surgery International, vol. 2017, Article ID 1283735, 9 pages, 2017. View at: Publisher Site | Google Scholar

Copyright © 2018 Felix J. Paprottka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

583 Views | 86 Downloads | 0 Citations
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.